Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06714253 · ClinicalTrials.gov registry record · Phase 1
Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1
A Phase 1 study of Radiation-Induced Xerostomia and Hyposalivation, sponsored by RiboX Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 4
- Study locations
NCT06714253 is a Phase 1 study of Radiation-Induced Xerostomia and Hyposalivation that is actively recruiting participants, run by RiboX Therapeutics. The registered enrollment target is 42 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT06714253, a Phase 1 study of Radiation-Induced Xerostomia and Hyposalivation, is actively recruiting participants, sponsored by RiboX Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a first-in-human clinical study to evaluate the safety, tolerability and efficacy of RXRG001 administered in the ducts of the parotid glands in adult patients with radiation-induced xerostomia (dry mouth) and hyposalivation (reduced saliva production). In Part 1 of the study (open-label, single-arm), patients will receive unilateral administrations of RXRG001 in 3 single ascending dose cohorts and in 3 multiple ascending dose cohorts. Part 2 of the study has a randomized, double-blind, placebo-controlled design. Patients will receive bilateral administrations of RXRG001 in 3 multiple ascending dose cohorts.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RXRG001
Study Locations (4)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Maryland
- John Hopkins University, Sidney Kimmel Comprehensive Cancer Center - Baltimore
New York
- NYU Langone Medical Center - New York
Pennsylvania
- Penn Medicine - Otorhinolaryngology - Head and Neck Surgery Perelman - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06714253
The ClinicalTrials.gov registry entry for NCT06714253 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RiboX Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Radiation-Induced Xerostomia and Hyposalivation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06714253 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Iowa, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT06714253 about?
NCT06714253 is a clinical study titled "Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1". This is a first-in-human clinical study to evaluate the safety, tolerability and efficacy of RXRG001 administered in the ducts of the parotid glands in adult patients with radiation-induced xerostomia (dry mouth) and hyposalivation (reduced saliva production). In Part 1 of the study (open-label, si...
What is the current status of trial NCT06714253?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2025-03-05. Estimated completion is 2027-08.
What conditions does trial NCT06714253 study?
This clinical trial studies the following conditions: Radiation-Induced Xerostomia and Hyposalivation.
What interventions are being tested in trial NCT06714253?
The interventions under investigation include: Placebo (BIOLOGICAL), RXRG001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06714253?
This trial is sponsored by RiboX Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06714253 being conducted?
This trial has 4 study locations across Iowa, Maryland, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.